Illumina, Mayo Clinic unite to ramp up next-gen genetic disorder testing

Illumina hq

Diagnostics giant Illumina is teaming up with Mayo Clinic to speed up the latter’s delivery of genetic and genomic expertise on inherited diseases. Mayo Clinic will test Illumina's next-gen tools and provide feedback to help Illumina in its ongoing product development.

Illumina's goal is to create an informatics system and knowledge base that can improve and automate the interpretation of genetics, according to a statement. To do this, the pair will combine their services and software and develop new tools to improve reporting workflows for Mayo Clinic’s research into inherited diseases.

Under the agreement, Mayo Clinic will test Illumina’s BaseSpace Clarity LIMS platform--a tool that tracks workflow and integration--in some of its labs. It will also report feedback to Illumina on its use of the BaseSpace Sequence Hub, a cloud-based genomics computing tool that manages and analyzes data, and the BaseSpace Variant Interpreter, a cloud-based platform built to cut down on the time and effort used in reporting and interpreting genomic data.


How ICON, Lotus, and Bioforum are Improving Study Efficiency with a Modern EDC

CROs are often at the forefront of adopting new technologies to make clinical trials more efficient. Hear how ICON, Lotus Clinical Research, and Bioforum are speeding database builds and automating reporting tasks for data management.

“Through this relationship, we will be able to generate large volumes of genomic information, interrogate the data, and then compare it to what’s known about those variants and those genetic aberrations in real time, saving our geneticists time,” said Dr. William Morice II, chair of Mayo’s Department of Laboratory Medicine and Pathology and president of Mayo Medical Laboratories, in the statement. “We are pleased to work with Illumina and to leverage each other’s expertise in genetic sequencing and analysis.”

This isn’t Illumina’s first tie-up with Mayo Clinic. In August last year, Illumina, Warburg Pincus and Sutter Hill launched Helix, a $100 million venture dedicated to providing consumers with low-cost sequencing and database services via third-party partners. Their first partner? The Mayo Clinic, which signed on to investigate applications based on consumer education and health-related queries.

Suggested Articles

AstraZeneca is linking up with DeepMatter, a big data firm focused on achieving reproducibility in chemistry, to help improve its compound synthesis.

The $210 million fund began life by leading a $17 million series A round in Quellis Biosciences.

The nine-story building will house Amgen’s Bay Area employees when it opens early in 2022.